Gene-editing firms form patent alliance against Editas, Broad
By Max Stendahl,
Boston Business Journal
| 12. 16. 2016
Four biotechs involved in the burgeoning field of gene editing announced a formal patent alliance on Friday that puts them at odds with two Cambridge institutions doing the same, Editas Medicine and The Broad Institute.
The four companies — Berkeley, California-based Caribou Biosciences, ERS Genomics of Ireland, and Cambridge-based firms CRISPR Therapeutics (Nasdaq: CRSP) and Intellia Therapeutics (Nasdaq: NTLA) — all licensed or sublicensed intellectual property regarding CRISPR/Cas9 gene-editing from the same source: biologist Emmanuelle Charpentier, the Regents of the University of California and the University of Vienna.
On the other side of the dispute is Editas (Nasdaq: EDIT), which has been using CRISPR technology developed by Feng Zhang of the Broad Institute.
Charpentier and Zhang have each received patents for CRISPR/Cas9, a method of cutting out and replacing part of a gene that has the potential to revolutionize the treatment of serious genetic disorders. Their backers — UC Berkeley and the Broad, respectively — are currently duking it out in a court case in Virginia before the U.S. Patent and Trademark Office. A decision is expected in coming...
Related Articles
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Hannah Thomasy, The Scientist | 03.15.2024
23andMe’s stock price since late 2020
23andMe, the first-off-the-blocks personal genomics company, has been struggling lately. In October, there were reports of a massive data breach focusing on 999,999 people with Ashkenazi heritage. The company eventually admitted that hackers had gained at least some access to 6.9 million profiles, and suggested that this was due to customers who had reused passwords. Even before news of the huge leak and the PR faux pas that followed, the company’s stock had...